<DOC>
	<DOCNO>NCT01734941</DOCNO>
	<brief_summary>The primary objective study evaluate compare safety efficacy Trichuris suis ovum ( TSO ) therapy ( versus placebo ) pediatric patient autism . Evaluation safety tolerability treatment TSO target population across dose range test consider primary objective , primary efficacy objective assessed via change baseline Aberrant Behavior Checklist ( ABC ) subscale score . Dose response consider primary objective well . Secondary assessment efficacy assess via : • The change baseline Clinical Global Impression scale ( CGI-I )</brief_summary>
	<brief_title>TSO Pediatric Autistic Spectrum Disorders</brief_title>
	<detailed_description>This randomize , three-arm double-blind , placebo-controlled , single-center study evaluate effect oral administration Trichuris suis ovum ( compare placebo ) treatment pediatric patient diagnose Autism . The target sample size randomize study approximately 60 , randomly assign 1:1:1 ratio one three treatment group : 1 . Placebo ( n= 20 patient ) . These patient receive blind dose placebo every week . 2 . 2500 TSO every week ( n= 20 patient ) . These patient receive blind dose TSO every week 3 . 7500 TSO every week ( n= 20 patient ) . These patient receive blind dose TSO every week Double-blind treatment give total 16 week . This study 3 phase : - Screening period , comprise 5 week prior Baseline ( Day 1 ) - Double-blind treatment period 16 week - An untreated follow-up period 26 week . Following informed consent , patient screen basis diagnosis autism , vital sign , clinical laboratory medical history physical examination . Eligible patient randomize double-blind treatment TSO 2500 every week , TSO 7500 every week , placebo every week , ratio 1:1:1 . During double-blind study phase , study drug provide clinic liquid form administer every week , start Baseline visit , Week 14 . Week 14 last double-blind treatment administration study , Week 16 primary time point assessment efficacy . Patients return clinic every week double blind treatment period . After completion double-blind phase , patient return clinic 26 week follow last dose study medication safety assessment stool sample culture .</detailed_description>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Child Development Disorders , Pervasive</mesh_term>
	<criteria>1 . Males female , age 6 17 year , inclusive 2 . Diagnosis via Diagnostic Statistical Manual Mental Disorders Forth Edition ( DSMIV ) confirm Autism Diagnostic Observation Schedule ( ADOSI ) : 3 . CGISeverity score &gt; 4 ABC irritability score &gt; 18 4 . Mental age &gt; 18 month 5 . Weight least ** kg 6 . Currently psychotropic medication free stable dose psychotropic medication least 3 month prior study . 7 . Willing comply schedule study visit protocol requirement 8 . Patient and/or guardian ability provide inform consent 1 . Previous diagnosis Rett 's Disorder , Aspergers Disorder , Childhood Disintegrative Disorder , Fragile X Syndrome , disorder autism spectrum 2 . History Bipolar Disorder , Psychotic Disorders , major Depression 3 . Seizure within previous 6 month 4 . Patient receive antibiotic , antifungal antiparasitic medication last 2 week prior Screening and/or would potentially require study treatment period 5 . Patient history drug alcohol abuse within 6 month prior Screening 6 . Patient evidence poor compliance medical advice instruction include diet medication 7 . Patient unable unwilling swallow study medication suspension 8 . Patient significant medical condition put patient risk study participation and/or reason consider Investigator unsuitable candidate receive TSO potentially put risk study procedures 9 . Patient participate another clinical trial within 30 day Screening trial and/or experimental treatment population 10 . Females childbearing potential unwilling unable use acceptable method avoid pregnancy entire study period 11 . Females pregnant breastfeeding time enrollment 12 . Patients follow laboratory value : 1 . White blood cell count ≤ 3,000/mm3 ( ≤ 3.0 x 109/L ) ≥ 14,000/mm3 ( ≥14 x 109/L ) 2 . Platelet count ≤ 100,000/μL ( ≤100 x 109/L ) 3 . Serum creatinine ≥ 1.5 mg/dL ( ≥ 132.6 μmol/L ) &gt; 2 x upper limit normal ( ULN ) 4 . AST ( SGOT ) ALT ( SGPT ) &gt; 2 x ULN 5 . Total bilirubin &gt; 2 mg/dL ( 34 μmol/L ) 6 . Hemoglobin &lt; 9 g/dL</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Autism</keyword>
	<keyword>Trichuris Suis Ova</keyword>
	<keyword>Behavior</keyword>
	<keyword>Irritability</keyword>
</DOC>